{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:43:12Z","timestamp":1790358192885,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejca.2021.09.035","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T21:08:19Z","timestamp":1635973699000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9882-4344","authenticated-orcid":false,"given":"Carl M.","family":"Thielmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Chorti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Matull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajmohan","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-2694","authenticated-orcid":false,"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-9626","authenticated-orcid":false,"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-9486","authenticated-orcid":false,"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-499X","authenticated-orcid":false,"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-7407","authenticated-orcid":false,"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-5963","authenticated-orcid":false,"given":"Eva","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9449","authenticated-orcid":false,"given":"Klaus G.","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ejca.2021.09.035_bib1","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10151","key":"10.1016\/j.ejca.2021.09.035_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.09.035_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2021.09.035_bib4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2021.09.035_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.ejca.2021.09.035_bib6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas N","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejca.2021.09.035_bib7","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2021.09.035_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.12.002","article-title":"The real-world impact of modern treatments on the survival of patients with metastatic melanoma","volume":"108","author":"Donia","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.09.035_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.09.035_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.09.035_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2021.09.035_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol\u202f: Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2021.09.035_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.09.035_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2021.09.035_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.09.035_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/phpp.12329","article-title":"Mechanisms and prevention of UV-induced melanoma","volume":"34","author":"Sample","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"10.1016\/j.ejca.2021.09.035_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","article-title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics","volume":"11","author":"Cirenajwis","year":"2017","journal-title":"Mol Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2021.09.035_bib18","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"6280","key":"10.1016\/j.ejca.2021.09.035_bib19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.ejca.2021.09.035_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejca.2021.09.035_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"10","key":"10.1016\/j.ejca.2021.09.035_bib22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/PAS.0000000000000451","article-title":"NF1 mutations are common in desmoplastic melanoma","volume":"39","author":"Wiesner","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2021.09.035_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov"},{"issue":"36","key":"10.1016\/j.ejca.2021.09.035_bib24","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.09.035_bib25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.09.035_bib26","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res\u202f: Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.09.035_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"issue":"16","key":"10.1016\/j.ejca.2021.09.035_bib28","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/bioinformatics\/btv195","article-title":"PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels","volume":"31","author":"Choi","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2021.09.035_bib29","series-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2020"},{"key":"10.1016\/j.ejca.2021.09.035_bib30","series-title":"RStudio: integrated development for R","author":"Team R","year":"2019"},{"issue":"6","key":"10.1016\/j.ejca.2021.09.035_bib31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/carcin\/bgw055","article-title":"Understanding mutagenesis through delineation of mutational signatures in human cancer","volume":"37","author":"Petljak","year":"2016","journal-title":"Carcinogenesis"},{"issue":"25","key":"10.1016\/j.ejca.2021.09.035_bib32","doi-asserted-by":"crossref","first-page":"40683","DOI":"10.18632\/oncotarget.16542","article-title":"Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations","volume":"8","author":"Cosgarea","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.09.035_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.05.014","article-title":"Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma","volume":"81","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2021.09.035_bib34","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1002\/cncr.24481","article-title":"Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma","volume":"115","author":"Anderson","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.09.035_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40487-020-00109-1","article-title":"Gender differences and outcomes in melanoma patients","volume":"8","author":"Morgese","year":"2020","journal-title":"Oncol Ther"},{"issue":"9","key":"10.1016\/j.ejca.2021.09.035_bib36","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ejca.2021.09.035_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2310\/7750.2011.11064","article-title":"KIT gene mutations and patterns of protein expression in mucosal and acral melanoma","volume":"16","author":"Abu-Abed","year":"2012","journal-title":"J Cutan Med Surg"},{"issue":"21","key":"10.1016\/j.ejca.2021.09.035_bib38","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res\u202f: Off J Am Assoc Cancer Res"},{"issue":"26","key":"10.1016\/j.ejca.2021.09.035_bib39","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.09.035_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2019.07.008","article-title":"Clinical and genetic analysis of melanomas arising in acral sites","volume":"119","author":"Zaremba","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.09.035_bib41","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"issue":"6122","key":"10.1016\/j.ejca.2021.09.035_bib42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejca.2021.09.035_bib43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejca.2021.09.035_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccr.2009.05.009","article-title":"Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis","volume":"16","author":"McGillicuddy","year":"2009","journal-title":"Cancer Cell"},{"issue":"7653","key":"10.1016\/j.ejca.2021.09.035_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2021.09.035_bib46","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:44Z","timestamp":1760733224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921011357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":46,"alternative-id":["S0959804921011357"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.09.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}